Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.

ABSTRACT: Overall survival of patients with hepatocellular carcinoma (HCC) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a multikinase inhibitor. To develop a more efficacious treatment, we undertook a feasibility study of personalized peptide vaccination (PPV) for HCC, in which the peptides were selected from 31 peptide candidates based on the pre-existing immunity. Twenty-six HCC patients refractory to locoregional therapies (cohort 1) and 30 patients refractory to both locoregional and systemic therapies (cohort 2) were entered into the study. There were no severe adverse events related to PPV except for one injection site reaction. At the end of the first cycle of six vaccinations, successful CTL or IgG boosting was observed in 57% or 46% of patients in c

SUBMITTER: Yutani S 

PROVIDER: S-EPMC5581512 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature